LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 68

Search options

  1. Article ; Online: Is it Time to Personalize Digital Health Interventions?

    Ghazi, Lama / Devore, Adam D

    Journal of cardiac failure

    2023  Volume 29, Issue 5, Page(s) 784–786

    Language English
    Publishing date 2023-03-24
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1281194-4
    ISSN 1532-8414 ; 1071-9164
    ISSN (online) 1532-8414
    ISSN 1071-9164
    DOI 10.1016/j.cardfail.2023.03.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Letter to the editor.

    Juraschek, Stephen P / Cohen, Jordana B / Ghazi, Lama

    Journal of hypertension

    2024  Volume 42, Issue 4, Page(s) 609

    Language English
    Publishing date 2024-02-29
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 605532-1
    ISSN 1473-5598 ; 0263-6352 ; 0952-1178
    ISSN (online) 1473-5598
    ISSN 0263-6352 ; 0952-1178
    DOI 10.1097/HJH.0000000000003673
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Inclusion of Middle Eastern and North African populations in diabetes clinical research.

    Nasser, Samar A / Ghazi, Lama / Abuelezam, Nadia N

    Journal of the National Medical Association

    2023  Volume 115, Issue 4, Page(s) 454–458

    Abstract: The need for diverse representation in clinical trials has recently been reinforced by the Food and Drug Administration's (FDA) guidance for industry entitled, "Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic ...

    Abstract The need for diverse representation in clinical trials has recently been reinforced by the Food and Drug Administration's (FDA) guidance for industry entitled, "Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials." By ensuring inclusion of underrepresented racial and ethnic minority populations in clinical trials, results can be more generalizable and the safety and efficacy can be accurately assessed within the diverse U.S. population. Limitations exist in the interpretation and implementation of clinical trial results reported using the current racial and ethnic categories, as these standards do not reflect the true diversity of the U.S. population. This is particularly true for the Middle Eastern and North African (MENA) population, which is usually overlooked given the lack of an established category. Although the international MENA region demonstrates the highest prevalence of diabetes in the world at 12.2%, the actual prevalence among MENA individuals living in the U.S. may be "hidden" within the White category. Therefore, data on the MENA population should be disaggregated from data within the White category to not only unmask health disparities, but also to ensure adequate representation in clinical trials. This paper discusses the importance of appropriate representation and inclusion of the MENA population in diabetes clinical trials, which is a critical public health issue domestically and globally.
    MeSH term(s) Humans ; Diabetes Mellitus/epidemiology ; Diabetes Mellitus/therapy ; Ethnicity ; Minority Groups ; North African People ; United States ; Middle Eastern People ; Clinical Trials as Topic ; Patient Selection
    Language English
    Publishing date 2023-07-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 419737-9
    ISSN 1943-4693 ; 0027-9684
    ISSN (online) 1943-4693
    ISSN 0027-9684
    DOI 10.1016/j.jnma.2023.06.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Hypertension in Women Across the Lifespan.

    Ghazi, Lama / Bello, Natalie A

    Current atherosclerosis reports

    2021  Volume 23, Issue 8, Page(s) 43

    Abstract: Purpose of review: We will highlight the biological processes across a women's lifespan from young adulthood through menopause and beyond that impact blood pressure and summarize women's representation in hypertension clinical trials.: Recent findings! ...

    Abstract Purpose of review: We will highlight the biological processes across a women's lifespan from young adulthood through menopause and beyond that impact blood pressure and summarize women's representation in hypertension clinical trials.
    Recent findings: Throughout their lifetime, women potentially undergo several unique sex-specific changes that may impact their risk of developing hypertension. Blood pressure diagnostic criteria for pregnant women remains 140/90 mmHg and has not been updated for concordance with the 2017 ACC/AHA guideline due to a lack of data. Although on a population level, women develop hypertension at later ages than men, new data shows women's BP starts to increase as early as the third decade. Understanding how age and sex both contribute to hypertension in elderly women is crucial to identify optimal blood pressure and treatment targets. Effective screening, monitoring, and treatment of hypertension throughout a women's lifespan are necessary to reduce CVD risk. We highlight several gaps in the literature pertaining to understanding sex-specific hypertension mechanisms.
    MeSH term(s) Adult ; Aged ; Blood Pressure ; Female ; Humans ; Hypertension/diagnosis ; Hypertension/epidemiology ; Longevity ; Male ; Menopause ; Pregnancy ; Risk Factors ; Young Adult
    Language English
    Publishing date 2021-06-19
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 2057369-8
    ISSN 1534-6242 ; 1523-3804
    ISSN (online) 1534-6242
    ISSN 1523-3804
    DOI 10.1007/s11883-021-00941-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Biomarkers vs Machines: The Race to Predict Acute Kidney Injury.

    Ghazi, Lama / Farhat, Kassem / Hoenig, Melanie P / Durant, Thomas J S / El-Khoury, Joe M

    Clinical chemistry

    2024  

    Abstract: Background: Acute kidney injury (AKI) is a serious complication affecting up to 15% of hospitalized patients. Early diagnosis is critical to prevent irreversible kidney damage that could otherwise lead to significant morbidity and mortality. However, ... ...

    Abstract Background: Acute kidney injury (AKI) is a serious complication affecting up to 15% of hospitalized patients. Early diagnosis is critical to prevent irreversible kidney damage that could otherwise lead to significant morbidity and mortality. However, AKI is a clinically silent syndrome, and current detection primarily relies on measuring a rise in serum creatinine, an imperfect marker that can be slow to react to developing AKI. Over the past decade, new innovations have emerged in the form of biomarkers and artificial intelligence tools to aid in the early diagnosis and prediction of imminent AKI.
    Content: This review summarizes and critically evaluates the latest developments in AKI detection and prediction by emerging biomarkers and artificial intelligence. Main guidelines and studies discussed herein include those evaluating clinical utilitiy of alternate filtration markers such as cystatin C and structural injury markers such as neutrophil gelatinase-associated lipocalin and tissue inhibitor of metalloprotease 2 with insulin-like growth factor binding protein 7 and machine learning algorithms for the detection and prediction of AKI in adult and pediatric populations. Recommendations for clinical practices considering the adoption of these new tools are also provided.
    Summary: The race to detect AKI is heating up. Regulatory approval of select biomarkers for clinical use and the emergence of machine learning algorithms that can predict imminent AKI with high accuracy are all promising developments. But the race is far from being won. Future research focusing on clinical outcome studies that demonstrate the utility and validity of implementing these new tools into clinical practice is needed.
    Language English
    Publishing date 2024-02-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    DOI 10.1093/clinchem/hvad217
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A Clinical Framework for Evaluating Machine Learning Studies.

    Ghazi, Lama / Ahmad, Tariq / Wilson, Francis Perry

    JACC. Heart failure

    2022  Volume 10, Issue 9, Page(s) 648–650

    MeSH term(s) Algorithms ; Heart Failure ; Humans ; Machine Learning
    Language English
    Publishing date 2022-08-10
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2705621-1
    ISSN 2213-1787 ; 2213-1779
    ISSN (online) 2213-1787
    ISSN 2213-1779
    DOI 10.1016/j.jchf.2022.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Screening for Hypertension in Children With and Without Autism Spectrum Disorder.

    Nugent, James T / Bakhoum, Christine / Ghazi, Lama / Greenberg, Jason H

    JAMA network open

    2022  Volume 5, Issue 4, Page(s) e226246

    MeSH term(s) Autism Spectrum Disorder/complications ; Autism Spectrum Disorder/diagnosis ; Autism Spectrum Disorder/epidemiology ; Child ; Humans ; Hypertension/complications ; Hypertension/diagnosis ; Hypertension/epidemiology ; Mass Screening ; Medical History Taking
    Language English
    Publishing date 2022-04-01
    Publishing country United States
    Document type Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2022.6246
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Antihypertensive medication persistence and adherence among non-Hispanic Asian US patients with hypertension and fee-for-service Medicare health insurance.

    Choi, Eunhee / Mizuno, Hiroyuki / Wang, Zhixin / Fang, Chloe / Mefford, Matthew T / Reynolds, Kristi / Ghazi, Lama / Shimbo, Daichi / Muntner, Paul

    PloS one

    2024  Volume 19, Issue 3, Page(s) e0300372

    Abstract: Background: Less than 50% of non-Hispanic Asian adults taking antihypertensive medication have controlled blood pressure.: Methods: We compared non-persistence and low adherence to antihypertensive medication between non-Hispanic Asian and other race/ ...

    Abstract Background: Less than 50% of non-Hispanic Asian adults taking antihypertensive medication have controlled blood pressure.
    Methods: We compared non-persistence and low adherence to antihypertensive medication between non-Hispanic Asian and other race/ethnicity groups among US adults ≥66 years who initiated antihypertensive medication between 2011 and 2018 using a 5% random sample of Medicare beneficiaries (non-Hispanic Asian, n = 2,260; non-Hispanic White, n = 56,000; non-Hispanic Black, n = 5,792; Hispanic, n = 4,212; and Other, n = 1,423). Non-persistence was defined as not having antihypertensive medication available to take in the last 90 of 365 days following treatment initiation. Low adherence was defined as having antihypertensive medication available to take on <80% of the 365 days following initiation.
    Results: In 2011-2012, 2013-2014, 2015-2016 and 2017-2018, the proportion of non-Hispanic Asian Medicare beneficiaries with non-persistence was 29.1%, 25.6%, 25.4% and 26.7% (p-trend = 0.381), respectively, and the proportion with low adherence was 58.1%, 54.2%, 53.4% and 51.6%, respectively (p-trend = 0.020). In 2017-2018, compared with non-Hispanic Asian beneficiaries, non-persistence was less common among non-Hispanic White beneficiaries (risk ratio 0.74 [95%CI, 0.64-0.85]), non-Hispanic Black beneficiaries (0.80 [95%CI 0.68-0.94]) and those reporting Other race/ethnicity (0.68 [95%CI, 0.54-0.85]) but not among Hispanic beneficiaries (1.04 [95%CI, 0.88-1.23]). Compared to non-Hispanic Asian beneficiaries, non-Hispanic White beneficiaries and beneficiaries reporting Other race/ethnicity were less likely to have low adherence to antihypertensive medication (relative risk 0.78 [95%CI 0.72-0.84] and 0.84 [95%CI 0.74-0.95], respectively); there was no association for non-Hispanic Black or Hispanic beneficiaries.
    Conclusions: Non-persistence and low adherence to antihypertensive medication were more common among older non-Hispanic Asian than non-Hispanic White adults.
    MeSH term(s) Adult ; Humans ; Aged ; United States ; Antihypertensive Agents/therapeutic use ; Medicare ; Hypertension ; Medication Adherence ; Ethnicity
    Chemical Substances Antihypertensive Agents
    Language English
    Publishing date 2024-03-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0300372
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Trends in All-Cause, Cardiovascular, and Noncardiovascular Mortality Among US Adults With Hypertension.

    Choi, Eunhee / Shimbo, Daichi / Chen, Ligong / Foti, Kathryn / Ghazi, Lama / Hardy, Shakia T / Muntner, Paul

    Hypertension (Dallas, Tex. : 1979)

    2024  Volume 81, Issue 5, Page(s) 1055–1064

    Abstract: Background: Death certificate data indicate that hypertension may have increased as a contributing cause of death among US adults. Hypertension is not commonly recorded on death certificates although it contributes to a substantial proportion of ... ...

    Abstract Background: Death certificate data indicate that hypertension may have increased as a contributing cause of death among US adults. Hypertension is not commonly recorded on death certificates although it contributes to a substantial proportion of cardiovascular disease (CVD) deaths.
    Methods: We estimated changes in all-cause, CVD, and non-CVD mortality over 5 years of follow-up among 4 cohorts of US adults with hypertension using mortality follow-up data from National Health and Nutrition Examination Survey III in 1988 to 1994, and National Health and Nutrition Examination Survey cycles from 1999 to 2000 through 2015 to 2016 (n=20 927). Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or antihypertensive medication use. Participants were grouped according to the date of their National Health and Nutrition Examination Survey study visit (1988-1994, 1999-2004, 2005-2010, 2011-2016).
    Results: There were 2646, 1048, and 1598 all-cause, CVD, and non-CVD deaths, respectively. After age, gender, and race/ethnicity adjustment and compared with the 1988 to 1994 cohort, the hazard ratio of all-cause mortality was 0.88 (95% CI, 0.76-1.01) for the 1999 to 2004 cohort, 0.82 (95% CI, 0.70-0.95) for the 2005 to 2010 cohort, and 0.89 (95% CI, 0.75-1.05) for the 2011 to 2016 cohort (
    Conclusions: The decline in CVD mortality among US adults with hypertension stalled after 2005 to 2010.
    MeSH term(s) Adult ; Humans ; Nutrition Surveys ; Hypertension ; Cardiovascular Diseases/etiology ; Blood Pressure/physiology ; Antihypertensive Agents/therapeutic use ; Risk Factors
    Chemical Substances Antihypertensive Agents
    Language English
    Publishing date 2024-02-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 423736-5
    ISSN 1524-4563 ; 0194-911X ; 0362-4323
    ISSN (online) 1524-4563
    ISSN 0194-911X ; 0362-4323
    DOI 10.1161/HYPERTENSIONAHA.123.22220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The association between fine particulate matter (PM

    Ghazi, Lama / Drawz, Paul E / Berman, Jesse D

    Journal of exposure science & environmental epidemiology

    2021  Volume 32, Issue 4, Page(s) 583–589

    Abstract: Background: Recent evidence has shown that fine particulate matter (PM: Objective: To investigate the association between PM: Methods: We estimated the previous 1-year average PM: Results: Patients (n = 20,289) in the fourth (PM: Significance! ...

    Abstract Background: Recent evidence has shown that fine particulate matter (PM
    Objective: To investigate the association between PM
    Methods: We estimated the previous 1-year average PM
    Results: Patients (n = 20,289) in the fourth (PM
    Significance: Exposure to higher PM
    MeSH term(s) Air Pollutants/adverse effects ; Air Pollutants/analysis ; Air Pollution/analysis ; Electronic Health Records ; Environmental Exposure/adverse effects ; Environmental Exposure/analysis ; Humans ; Minnesota/epidemiology ; Particulate Matter/adverse effects ; Particulate Matter/analysis ; Renal Insufficiency, Chronic/chemically induced ; Renal Insufficiency, Chronic/epidemiology
    Chemical Substances Air Pollutants ; Particulate Matter
    Language English
    Publishing date 2021-06-14
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2218551-3
    ISSN 1559-064X ; 1559-0631
    ISSN (online) 1559-064X
    ISSN 1559-0631
    DOI 10.1038/s41370-021-00351-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top